XML 95 R83.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Subsequent Events (Details) $ / shares in Units, $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 29, 2024 USD ($) | Apr. 23, 2024 USD ($) | Apr. 03, 2024 Right $ / shares | Feb. 27, 2024 USD ($) | Oct. 30, 2023 USD ($) | Mar. 22, 2021 USD ($) | Apr. 30, 2024 USD ($) | Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($)
Subsequent Event |  |  |  |  |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  |  |  |  |  |  | $ 15,000 | $ 9,600
Revenue from contracts with customers |  |  |  |  |  |  |  | 1,000 |
Kinnate | Exarafenib and related IP | Disposed of by Sale, Not Discontinued Operations |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Cash consideration received |  |  |  | $ 500 |  |  |  |  |
Contingent consideration to be received upon achievement of specified milestones |  |  |  | $ 30,500 |  |  |  |  |
Viracta | Royalty Purchase Agreement |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Amount of milestone payments earned under agreement |  |  |  |  | $ 5,000 |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  |  |  |  | $ 13,500 |  |  |
Rezolute | License Agreement |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Revenue from contracts with customers |  |  |  |  |  |  |  | $ 0 | $ 0
Subsequent Event | CVR Agreement | Exarafenib and related IP |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Percentage of further net proceeds from transaction |  |  | 100.00% |  |  |  |  |  |
Percentage of net proceeds from any license or other disposition |  |  | 85.00% |  |  |  |  |  |
Subsequent Event | Viracta | Royalty Purchase Agreement |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Amount of milestone payments earned under agreement |  | $ 9,000 |  |  |  |  |  |  |
Subsequent Event | Dare | Royalty Purchase Agreement |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs | $ 22,000 |  |  |  |  |  |  |  |
Percentage of remaining royalties | 100.00% |  |  |  |  |  |  |  |
Subsequent Event | Dare | Royalty Purchase Agreement | OVAPRENE and Sildenafil Cream | Upon achievement of a pre-specified return threshold |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Percentage of royalty which will decrease | 3.60% |  |  |  |  |  |  |  |
Subsequent Event | Dare | Royalty Purchase Agreement | OVAPRENE |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Royalties entity has right to receive (as a percent) | 4.00% |  |  |  |  |  |  |  |
Subsequent Event | Dare | Royalty Purchase Agreement | OVAPRENE | Upon achievement of a pre-specified return threshold |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Royalties entity has right to receive (as a percent) | 2.50% |  |  |  |  |  |  |  |
Subsequent Event | Dare | Royalty Purchase Agreement | Sildenafil Cream |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Royalties entity has right to receive (as a percent) | 2.00% |  |  |  |  |  |  |  |
Subsequent Event | Dare | Royalty Purchase Agreement | Sildenafil Cream | Upon achievement of a pre-specified return threshold |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Royalties entity has right to receive (as a percent) | 1.25% |  |  |  |  |  |  |  |
Subsequent Event | Rezolute | License Agreement |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Revenue from contracts with customers |  |  |  |  |  |  | $ 5,000 |  |
Subsequent Event | Kinnate |  |  |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |
Cash amount of consideration per outstanding share (in dollars per share) | $ / shares |  |  | $ 2.5879 |  |  |  |  |  |
Number of non-transferable contingent value rights for each acquiree share | Right |  |  | 1 |  |  |  |  |  |

X
- Definition Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfOtherProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of non-transferable contingent value rights each acquiree share has right to receive. representing right to receive one or more potential cash payments. + References No definition available. + Details
Name: | xoma_AcquisitionNumberOfContingentValueRights
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contingent consideration to be received as part of consideration in sale of assets. + References No definition available. + Details
Name: | xoma_ContingentConsiderationFromSaleOfAssets
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of milestone achieved. + References No definition available. + Details
Name: | xoma_MilestoneAchieved
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + References No definition available. + Details
Name: | xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash amount of consideration transferred in acquisition of a business measured by per outstanding share of acquiree's common stock. Includes base price and additional contingent amount. + References No definition available. + Details
Name: | xoma_PaymentToAcquireBusinessPricePerShareCashAmount
Namespace Prefix: | xoma_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net proceeds contingent value right holders have right to receive within one year of the merger closing date under the terms of the agreement from license or disposition entered into by acquiree. + References No definition available. + Details
Name: | xoma_PercentageOfProceedsPayableLicenseOrDisposition
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net proceeds contingent value right holders have right to receive until the fifth anniversary of the merger closing date under the terms of the agreement from sale entered into by acquiree. + References No definition available. + Details
Name: | xoma_PercentageOfProceedsPayableSale
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalties applicable under terms of agreement. + References No definition available. + Details
Name: | xoma_RoyaltyPercentageApplicableUnderAgreement
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalties subject to decrease under specified conditions under terms of agreement. + References No definition available. + Details
Name: | xoma_RoyaltyPercentagePercentageSubjectToDecrease
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalties entity has the right to receive as a percentage of net sales. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=xoma_KinnateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=xoma_ExarafenibAndRelatedIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_RezoluteIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_DareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_OvapreneAndSildenafilCreamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=xoma_ScenarioOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_OvapreneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_SildenafilCreamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=xoma_KinnateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |